Taylor Hoffman Wealth Management Purchases 334 Shares of Amgen, Inc. (NASDAQ:AMGN)

Share on StockTwits

Taylor Hoffman Wealth Management increased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 21.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,890 shares of the medical research company’s stock after purchasing an additional 334 shares during the period. Taylor Hoffman Wealth Management’s holdings in Amgen were worth $366,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in AMGN. Clear Harbor Asset Management LLC increased its holdings in Amgen by 0.8% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 6,385 shares of the medical research company’s stock valued at $1,236,000 after acquiring an additional 49 shares during the last quarter. Carlton Hofferkamp & Jenks Wealth Management LLC increased its holdings in Amgen by 1.1% in the 3rd quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 4,694 shares of the medical research company’s stock valued at $933,000 after acquiring an additional 50 shares during the last quarter. Independence Bank of Kentucky increased its holdings in Amgen by 3.5% in the 3rd quarter. Independence Bank of Kentucky now owns 1,645 shares of the medical research company’s stock valued at $318,000 after acquiring an additional 55 shares during the last quarter. Carroll Financial Associates Inc. increased its holdings in Amgen by 0.8% in the 2nd quarter. Carroll Financial Associates Inc. now owns 7,436 shares of the medical research company’s stock valued at $1,370,000 after acquiring an additional 58 shares during the last quarter. Finally, Lincoln Capital Corp increased its holdings in Amgen by 0.3% in the 2nd quarter. Lincoln Capital Corp now owns 21,483 shares of the medical research company’s stock valued at $3,959,000 after acquiring an additional 58 shares during the last quarter. Hedge funds and other institutional investors own 76.33% of the company’s stock.

Shares of AMGN stock traded up $3.12 during trading hours on Friday, reaching $221.11. 2,069,900 shares of the stock were exchanged, compared to its average volume of 2,911,719. Amgen, Inc. has a 12-month low of $166.30 and a 12-month high of $221.25. The company has a current ratio of 2.89, a quick ratio of 2.59 and a debt-to-equity ratio of 2.54. The firm has a market capitalization of $127.80 billion, a price-to-earnings ratio of 15.35, a price-to-earnings-growth ratio of 2.21 and a beta of 1.09. The company’s 50-day moving average price is $202.75 and its 200-day moving average price is $188.90.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 EPS for the quarter, beating the consensus estimate of $3.53 by $0.13. Amgen had a net margin of 34.48% and a return on equity of 80.26%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.63 billion. During the same quarter in the previous year, the business posted $3.69 EPS. The company’s quarterly revenue was down 2.8% compared to the same quarter last year. On average, sell-side analysts expect that Amgen, Inc. will post 14.44 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 6th. Stockholders of record on Friday, November 15th will be issued a $1.45 dividend. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $5.80 annualized dividend and a dividend yield of 2.62%. Amgen’s dividend payout ratio is currently 40.28%.

A number of equities analysts have commented on AMGN shares. Citigroup reissued a “buy” rating on shares of Amgen in a research note on Monday, August 12th. William Blair reissued a “hold” rating on shares of Amgen in a research note on Friday, August 30th. Royal Bank of Canada reissued a “hold” rating on shares of Amgen in a research note on Monday, September 30th. Morgan Stanley dropped their price objective on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a research note on Monday, July 15th. Finally, Leerink Swann lifted their price objective on shares of Amgen from $189.00 to $205.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $219.56.

In related news, SVP Cynthia M. Patton sold 13,426 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $208.07, for a total transaction of $2,793,547.82. Following the completion of the transaction, the senior vice president now owns 32,648 shares in the company, valued at approximately $6,793,069.36. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $206.70, for a total transaction of $413,400.00. Following the transaction, the director now owns 16,336 shares of the company’s stock, valued at approximately $3,376,651.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,851 shares of company stock valued at $3,685,674. Company insiders own 0.25% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: How to identify percentage decliners

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.